Company Name Conatus Pharmaceuticals
Mailing Address 4365 Executive Drive San Diego, CA 92121
Company Description The Conatus team pioneered the science of apoptosis and the clinical development of pan caspase inhibitors, validating this first-in-class technology. Conatus has well established relationships with key opinion leaders in the fields of hepatology, infectious disease and inflammation.
Proceeds Purposes The additional investment by MPM enables Conatus to move ahead assertively with its confirming Phase 2b clinical trial of CTS-1027 started in January 2011 as well as allowing for a thorough evaluation of the development compounds of Idun Pharmaceuticals acquired in 2010.